

P1 1183851

REC'D 23 JUN 2004

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

June 17, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/457,752

FILING DATE: March 26, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/09044

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



M. Tarver

M. TARVER
Certifying Officer

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

03/26/03

6598 U.S. PTO

03-27-03

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET


This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV242040536US

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Spiros Ligia		Fotinos Panaitescu		Kolonaki, Athens, Greece Ano Dasos Chaidariou, Attiki, Greece	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
Methods and Devices for Holding a Therapeutic Composition					
Direct all correspondence to:					
CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer, Number		002101		Place Customer Number Bar Code Label here	
OR		Type Customer Number here			
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification		Number of Pages		14	
<input checked="" type="checkbox"/> Drawing(s)		Number of Sheets		3	
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		<input type="checkbox"/> CD(s), Number			
		<input type="checkbox"/> Other (specify)			
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees				160.00	
<input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE



Date

03/26/03

TYPED or PRINTED NAME Robert M. Asher

TELEPHONE 617-443-9292

REGISTRATION NO.

(if appropriate)

Docket Number:

30,445

1581/135

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Practitioner's Docket No. 1581/135

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Spiros Fotinos, Ligia Panaitescu

Application No.: not yet assigned

Group No.: N/A

Filed: herewith

Examiner: N/A

For: Methods and Devices for Holding a Therapeutic Composition

Commissioner for Patents
Washington, D.C. 20231

EXPRESS MAIL CERTIFICATE

"Express Mail" label number EV 242040536 US


Date of Deposit 03/26/2003

I hereby state that the following *attached* paper or fee

provisional patent application and related papers

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Robert M. Asher


Signature of person mailing paper or fee

Inventor Information

Inventor One Given Name:: Spiros
Family Name:: Fotinos
Postal Address Line One:: 18A I. Statha Str.
City:: Kolonaki, Athens
Country: Greece
Postal or Zip Code:: 106-72
Citizenship Country:: GR

Inventor Two Given Name:: Ligia
Family Name:: Panaitescu
Postal Address Line One:: 22, Naxou Str.
City:: Ano Dasos Chaidariou, Attiki
Country: Greece
Postal or Zip Code:: 124-61
Citizenship Country:: GR

Correspondence Information

Correspondence Customer Number:: 2101

Application Information

Title Line One:: Methods and Devices for Holding a
Title Line Two: Therapeutic Composition
Total Drawing Sheets:: 3
Formal Drawings:: No
Application Type:: Provisional
Docket Number:: 1581/135

Representative Information

Representative Registration Number:: 30,445

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PROVISIONAL PATENT APPLICATION

FOR

Methods and Devices for Holding a Therapeutic Composition

Inventors: Spiros Fotinos
18A I. Statha Str.
Kolonaki, Athens
Greece
106-72

Ligia Panaitescu
22, Naxou Str.
Ano Dasos Chaidariou, Attiki
Greece
124-61

Attorney Docket: 1581/135

Attorneys: BROMBERG & SUNSTEIN LLP
125 Summer Street
Boston, MA 02110
(617) 443-9292

Attorney Docket: 1581/135

Methods and Devices for Holding a Therapeutic Composition**Background of the Invention**

The present invention relates to techniques and devices for packaging or holding
5 objects that have a therapeutic composition.

In manufacturing pharmaceuticals and other substances to induce some type of
therapeutic effect, an important consideration is how the quantities, or specific doses, of the
therapeutic composition are distributed to the consumer. Techniques of manufacturing the
therapeutic composition should be integrated with methods and devices for holding and/or
10 packaging the composition; this may allow advantages such as streamlining production labor
and decreased manufacturing costs. In the particular instance where the therapeutic
composition is embodied with an active agent-containing film, the film may be relatively
sensitive, fragile, and easily deformable or damaged. Thus, integrating manufacturing
techniques with design considerations for packaging and holding therapeutics may have the
15 added advantages enhancing product stability and quality. Simultaneously, the risk of
product deterioration may be decreased by minimizing exposure of the product to the
environment (e.g. light, air, heat, moisture, etc.), isolating the product from contact with
people, and facilitating product handling (e.g. preventing the stacking of films that may
adhere to one another).

20

Summary of the Invention

In a first embodiment of the invention, a device for holding therapeutic compositions
includes a support substrate; a pattern of adhesive applied to a side of the support substrate;
and an array of discrete film segments that are removably attached to the support substrate
through contact with the adhesive. The support substrate may be made of a transparent
25 material; in addition, the substrate may be a release liner. The pattern of adhesive may be a
set of parallel lines. The embodiment may be sterilized or packaged in a separate container
or pouch.

A method for producing the first embodiment first involves providing a pattern of adhesive applied to a side of a final support substrate. A film with the therapeutic composition is removably attached to the final support substrate through contact with the pattern of adhesive. Finally, the film is segmented into an array of discrete film segments that remain attached to the final support substrate through contact with the pattern of adhesive. Before the film is removably attached to the final support substrate, the film may also be removably attached to an initial support substrate. In that case, the initial support substrate is delaminated from the film before the film is segmented. The initial film substrate may have a coated surface of Teflon or silicon. Segmenting the film may include removing portions of the film that are not film segments.

In a second embodiment of the invention, another device for holding therapeutic compositions includes a support substrate; an array of discrete film segments carrying the therapeutic composition, that are removably attached to a side of the support substrate; and a sealing material that is heat sealed to the support substrate and covers the array of film segments. The support substrate may be made of a transparent material. The support substrate may also be a polyethylene-coated paper, wherein the side of the support substrate that contacts the film segments is glossy and unexposed to Corona treatment. The sealing material may be made of a material that is transparent, or may be tear resistant. One type of sealing material that may be used with the second embodiment is a polyester sheet double-side coated with polyethylene, the side of the sealing material heat sealed to the support substrate being glossy; the polyester sheet may also be ultra-dimensional stable. The sealing material may also be heat sealed around each film segment to isolate the film segments from one another. Another heat-sealing arrangement that may be used is to avoid heat sealing the corners of the support substrate to allow easier separation of the support substrate from the sealing material by a user. The embodiment may be sterilized.

A method for producing the second embodiment involves applying a film including the therapeutic composition to a portion of a side of a support substrate; segmenting the film into an array of film segments, the film segments being removably attached to the support substrate; superposing a sealing material to cover the film segments; and heat sealing the sealing material to the support substrate. The step of applying a film may include applying a polymer gel or polymer solution to the support substrate and allowing the solution or gel to

dry thus forming the film. The step of segmenting the film may include removing a portion of the film.

In a third embodiment of the invention, an alternate method for holding a therapeutic composition involves depositing each of a plurality of film segments into blister cavities
5 formed in a substrate; superposing a sealing material over the blister cavities and in contact with the substrate; and attaching the sealing material to the substrate. The step of attaching the sealing material may include heat sealing the sealing material to the substrate. Polyvinyl chloride, a combination of polyvinyl chloride and polyvinylidene chloride, or aluminum may be used for the substrate. The substrate material may be transparent. The sealing material
10 may be transparent, or may be tear-resistant. One type of material that may be used for the sealing material is lacquered aluminum foil.

A variation of the third embodiment includes practicing the step of depositing each of a plurality of film segments into blister cavities formed in a substrate by depositing film segments on the substrate and forming blister cavities in locations of the substrate where film
15 segments are deposited. In a second variation, the step of depositing each of a plurality of film segments into blister cavities is performed by laminating a film on the substrate and segmenting the film into segments while substantially simultaneously forming blister cavities in the substrate, at positions where film segments are created. In a third variation, the step of depositing each of a plurality of film segments into blister cavities is performed by forming a
20 plurality of blister cavities in a substrate, laminating a film over the substrate on a side such that the blister cavities protrude away from the film, and impinging a punch against the film on a side opposite the substrate, causing film segments to be created and deposited into the blister cavities.

The method of the third embodiment may also be practiced by omitting the steps of
25 covering the blisters with a film and displacing segments of the film. These steps are replaced by the providing of quantities of the therapeutic composition that are individually placed in the blisters of the substrate.

When film segments are used with the three embodiments, the film segments may be formed such that each contains the same quantity of a therapeutic composition. The amount
30 of therapeutic composition in a film segment may correspond with a particular dose of the therapeutic composition.

All of the methods described may be carried out by a continuous process. In addition, the methods may be modified to create a sterile product.

The invention will more readily be understood by reference to the following description taken with the accompanying drawings that depict various embodiments. The drawings are intended to provide a better understanding of the invention, but are in no way intended to limit the scope of the invention.

Brief Description of the Drawings

The foregoing features of the invention will be more readily understood by reference to the following detailed description, taken with reference to the accompanying drawings, in which:

Fig. 1a is a plan view of a device for holding therapeutic compositions in accordance with an embodiment of the invention.

Fig. 1b is a side view of a device for holding therapeutic compositions in accordance with an embodiment of the invention.

Figs. 2a - 2c is a series of side views illustrating the steps for making a device for holding film segments to a substrate material, covered by a sealing material, embodiment.

Figs. 3a - 3c is a series of schematic side views of the steps for making a device for holding therapeutic compositions in a blister cavity-formed substrate attached to a sealing material embodiment.

Detailed Description of Specific Embodiments

The embodiments described herein refer to methods and devices for holding a plurality of therapeutic compositions. The methods and devices may be employed to hold a plurality of film segments having the therapeutic composition. The film segments may be formed from a film that includes the therapeutic composition and may be configured in any desired shape and size.

For some embodiments described herein, the film segments 115, 215, 315 may be composed from a film of dried polymer solution or dried polymer gel, either of which may also be hydrophilic in nature before drying occurs. The polymer gel or polymer solution may be formulated with a level of viscosity sufficient to allow the gel or solution to hold a

specific configuration while drying occurs. The drying time depends upon a variety of factors that may include the type of solvents used, their concentration, the nature and concentration of the other constituents, the film thickness, the sensitivity of active components to high temperature, the air mass convected over the gel or solution, and the speed of film formation. For example, with heat sensitive materials, relatively low temperatures are preferred, requiring longer drying periods. Some embodiments may require a drying time of several minutes.

Polymers that may be utilized in the film segments 115, 215, 315, and the film 110, 210, 310, include, for example, polyurethane, polyvinyl pyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC). A variety of materials including cellulose, starch and their derivatives, proteins, gelatins, etc may also be used. Other polymers include polymers of natural origin. One such embodiment is a plant prolamine, an example being gliadin, combined with other additives of natural origin; such additives may include a polar lipid, such as a ceramide. Each film segment 115, 215, 315 contains some amount of the therapeutic composition to be delivered. A solvent, preferably ethanol when PVP or HPMC is used, is added to the polymer to make the solution.

The therapeutic composition utilized in the film may belong to any therapeutic category. Examples of possible therapeutic compositions include pharmaceuticals, cosmetics, food supplements, herbals, and botanicals. The therapeutic composition may be directed toward oral or topical application, such as epidermal, transdermal, or transmucosal. The amount of therapeutic composition may be the same in each film segment 115, 215, 315, and may also constitute a particular dosage of the therapeutic composition.

Embodiments of the dried polymer film segments have thicknesses of 0.03, 0.05, and 0.06 millimeters, each segment having a surface area varying between 0.8 and 3.0 square centimeters. The film may also contain additional components that alter particular physical and chemical properties. For example, a film may include a plasticizer and an antioxidant.

In a specific example, dried polymer film segments include an active agent for treating erectile dysfunction, a polymer, a plasticizer, and an antioxidant. The dried film segments are circularly shaped with a surface area of 2.0 cm^2 and a thickness of 0.05 mm.

Though the embodiments described herein refer specifically to holding film segments with a therapeutic composition, these embodiments may also be used to hold other carriers

with the therapeutic composition including various types of transdermal, epidermal, or transmucosal delivery systems (e.g. patches), tablets, capsules, and pills.

In some instances, sterilization of the device holding the therapeutic compositions helps preserve the compositions in a particular state before their use. Thus alternatives to the
5 embodiments described herein include application of methods and techniques known in the art to create the therapeutic compositions, carriers such as the film segments **115**, **215**, **315**, substrates **100**, **200**, **300**, adhesive **140**, sealing materials **220**, **320**, and other materials in a sterile manner.

Referring to Fig. 1, a support substrate **100** is shown holding a plurality of film
10 segments **115** each having an amount of the therapeutic composition. The film segments **115** are removably attached to the support substrate **100** by an adhesive **140**, allowing the film segments **115** to be separated from the support substrate **100** by a user without damaging the segments **115**.

The support substrate **100** may be composed of any type of material that allows the
15 film segments **115** to be removably attached to the support substrate **100** with an appropriate adhesive **140**. Preferred substrate materials include polyester, polystyrene, high density polyethylene, Teflon, paper, super-calendered (smoothed) paper, and polyurethane films. Laminates of the aforementioned materials may also be utilized. The support substrate **100** may be a release liner for the film segments **115**. In addition, the support substrate **100** may
20 be transparent, allowing a person to view the film segments **115** through the support substrate **100**.

The adhesive **140** may be applied in a particular pattern on the support substrate **100**. For example, the adhesive **140** may constitute sets of closely spaced parallel lines **145** that
25 allow the film segments **115** to be arranged in the pattern of a rectangular matrix, as depicted in Fig. 1a. In a particular embodiment, the adhesive is applied in three pairs of adhesive lines, each lines being approximately 80 millimeters long, 2 millimeters wide, and 0.02 millimeters thick. The adhesive **140** allows the film segments **115** to be removably attached to the support substrate **100**. In addition, the adhesive **140** is chosen such that it does not adversely affect the chemical or physical nature of the therapeutic composition or film
30 segments **115**. Examples of possible adhesives for use with the embodiment include, but are

not limited to, Duro-Tak® (produced by National Starch), Gelva® (produced by Solutia), and other commercially available polyacrylic adhesives.

One method for making the device depicted in Fig. 1a includes the steps of: (a) providing a final support substrate **100** with a pattern **145** of adhesive **140** in contact with a side of the support substrate **100**; (b) removably attaching a film **110** with the therapeutic composition to the final support substrate **100** through contact with the pattern of adhesive **145** as shown in Fig. 1b; and (c) segmenting the film **110** to form an array of film segments **115** attached to the final support substrate **100** through contact with the adhesive **140**. In a particular embodiment of the method, the step of removably attaching the film **110** to the final support substrate **100** includes providing the film **110** with the therapeutic composition removably attached to an initial support substrate; bringing the film **110** in contact with the pattern of adhesive **140**; and delaminating the initial support substrate from the film **110**, leaving the film **110** attached to the final support substrate **100**.

In the particular method described above, the initial support substrate may be composed of any material that has the property of adhering to the film **110** more weakly than the final support substrate **100** adheres to the film **110**. The film's adherence to the initial support substrate may be an intrinsic property of the two surfaces, or may be facilitated by the use of an adhesive. Possible initial support substrates include release liners. Release liners for the initial support substrate may include a side, which contacts the film **110**, being coated with either silicon or Teflon.

Segmenting the film **110** into an array of film segments **115** may include one or more processes, non-exhaustive examples being cutting and removing of the film **110**. In a particular segmenting process, kiss-cutting of the film **110** is performed. Kiss-cutting involves making cuts that penetrate the film **110**, while not penetrating the support substrate **100**. The kiss-cutting is followed by removal of a portion of the film from the support substrate **100**, leaving discrete film segments **115** that adhere to the support substrate **100** by contact with adhesive **140**, as depicted in Fig. 1a. The remaining film that is not utilized as film segments **115** may be discarded or recycled to formulate more film.

The steps of the method may be performed to produce a continuous product. In such an instance, an additional step of cutting the final support substrate **100** with attached film segments **115** into discrete sets is included. Machinery, such as the Allied Gear and Machine

Co.'s Flexomaster IB press, may be utilized to perform one or more steps of the method continuously. In an embodiment of the method, the step of segmenting the film may be performed by the Flexomaster IB press. In this embodiment, the film 110, support substrate 100, and adhesive 140 are provided as a continuous laminate that is rolled up. The laminate is unrolled by the machine and kiss-cut by a first cutting tool, and perforated and scored by a second cutting tool. The machine may also be configured to perform some preprocessing steps on the laminate before kiss cutting occurs. The cutting tools are configured to accommodate the specific film thickness and support substrate utilized. Film 110 that is not utilized in the therapeutic composition, scrap, is delaminated from the original laminate and wound up in a roll. The remaining laminate, including film segments 115 attached to a support substrate 100 through contact with adhesive 140, is rewound on a roll for further processing.

One or more sets of the film segments 115 attached to the final support substrate 100 may be packaged in a pouch, or other container, to protect the assembly from potential hazards that may include physical damage, contamination, light exposure, or other environmental elements.

Another embodiment of a device for holding a therapeutic composition is shown in Fig. 2c. In this embodiment, film segments 215 are removably attached to a support substrate 200 without the use of an adhesive; adhesion of the film segments 215 to the support substrate 200 is due to the nature of the interaction between the segments 215 and the support substrate 200. Minor self-adhesive properties of the film segments, substrate surface roughness (surface irregularities created by a particular treatment method), and temporarily induced electrostatic charges provide some examples of mechanisms that result in adhesion between the segments 215 and support substrate 200. A sealing material 220 covers the film segments 215 so that the segments are protected in a sandwich between the support substrate 200 and the sealing material 220. The sealing material 220 is heat sealed to the support substrate 200, to enclose the film segments in a sealed package. The film segments 215 are protected from potential hazards that may include physical damage, contamination, light exposure, and other environmental conditions.

The support substrate 200 may be composed of any type of material that allows the film segments 215 to be removably attached to the support substrate 200 and does not cause

adverse physical or chemical changes to the nature of the therapeutic composition or film segments 215. Examples of acceptable support substrate materials include paper or plastic sheets. The support substrate 200 may be a release liner. In a particular embodiment, the support substrate 200 is composed of a polyethylene-coated paper. The side of the
5 polyethylene-coated paper that adheres to the film segments 215 is glossy, and not Corona treated, i.e. the side has a smooth, reflective surface that has not been treated to introduce any surface irregularities. This insures that adhesion of the film segments 215 to the support substrate 200 is not so strong as to prevent the segments 215 from being removed without damage. The support substrate 200 may be also be made of a transparent material, allowing
10 persons to view the film segments through the support substrate 200.

One embodiment of a sealing material 220 utilizes a polyester sheet double side coated with polyethylene, the surface of the film that contacts the support substrate 200 being glossy. In particular, this embodiment of the sealing material 220 may be configured to be especially stable. Examples of the embodiment include the ultra-dimensional stable
15 polyester films produced by Loparex. The films are polyester films coated with a layer of low-density polyethylene on each side. The films do not lose moisture when heated, and, therefore, do not change their dimensions upon heating. The films are very stable liners that do not tend to curl.

The sealing material 220 may be composed of any material that may be heat sealed to
20 the support substrate 200. The sealing material 220 may be transparent, allowing the film segments 215 to be seen through the sealing material 220. The sealing material 220 may also be chosen to be tear resistant.

The sealing material 220 may be heat sealed to the support substrate 200 such that each film segment 215 is isolated from the other film segments 215. The sealing material
25 may also be intentionally unattached to the support substrate in particular locations, e.g. the corners of the sealing material, to allow ease of separation of the sealing material from the support substrate by a user.

As shown in Figs. 2a - 2c, a method for making the device includes the steps of applying a film 210 having the therapeutic composition to a side of a support substrate 200;
30 segmenting the film 210 into film segments 215; covering the film segments 215 with a sealing material 220; and heat sealing the sealing material 220 to the support substrate 200.

The film segments 215 are attached to the support substrate 200, but may be removed therefrom without damage to the film segments 215. In particular, the method may include using a polymer gel or polymer solution to make the film 210, and include the step of drying the film 210 after the film 210 is applied to a support substrate 200.

5 The step of segmenting the film 210 may include kiss-cutting the film 210 and removing the film portions that are not utilized as film segments 215 on the support substrate 200. Excess film may either be discarded or recycled to formulate more film. A continuous process may be employed to carry out the steps of this method; in such a case, the method further includes a step of cutting the attached support substrate 200 and sealing material 220
10 holding a plurality of film segments 215 to create sets of the held film segments 215.

 In a preferred embodiment of the method, a coating machine applies the polymer solution or polymer gel to the support substrate, forming a laminate sheet. The solution or gel is dried, and the laminate wound up into a roll. The Allied Gear and Machine Co.'s Flexomaster IB press, that was described earlier to create the embodiment in Fig. 1, can be
15 utilized with the roll created by the coating machine to kiss-cut and delaminate the scrap material not being packaged.

 Referring to Figs. 3a - 3c, an alternate method of producing a device for holding film segments with a therapeutic composition is described. Discrete film segments 315 including the therapeutic composition are deposited into individual blisters cavities 305 of a substrate
20 material 300. The film segments 315 may be formed from an original film 310 containing the therapeutic composition. A sealing material 320 is placed over the blisters cavities 305 containing the film segments 315 and attached to the substrate material 300 to contain the film segments 315. The film segments 315 may be free from attachment while contained within the blister cavity 305 covered by the sealing material 320.

25 The substrate material 300 may be any material to which blisters cavities 305 may be formed. Blister cavities 305 are stable impressions in the substrate material 300 that are sized to contain individual film segments 315, as depicted in Figs. 3b and 3c. When the substrate 300 is oriented such that the blisters 305 are in a concave downward orientation, as depicted in Figs. 3a - 3c, individual film segments 315 may be contained within each blister
30 cavity 305, with an open top surface as depicted in Fig. 3b. Examples of suitable materials

for the substrate material **300** include, but are not limited to, polyvinyl chloride, a combination of polyvinyl chloride and polyvinylidene chloride, and aluminum.

The formation of blister cavities **305** in the substrate material **300** and depositing of film segments **315** into the blister cavities **305** may be performed using various techniques.

5 In one technique, film segments **315** are provided on a blister cavity-free substrate material. The film segments **315** may be formed and provided on the substrate material **300** utilizing the methods described earlier to form the embodiments depicted by Fig. 2. The film segments **315** may be held in place on the substrate material **300** by electrostatic charges.

Next, a machine forms blister cavities **305** in the substrate material **300** at positions where

10 film segments **315** are located. The blister cavities **305** may be formed by any technique known to those in the art. In one embodiment, the blister cavities **305** are formed by moving the substrate **300** over an appropriately sized and shaped orifice in a surface of a machine. The substrate material **300** is drawn into the orifice, deforming permanently into a shape confined by the orifice and creating the blister cavity **305**. The process of deforming the

15 substrate material **300** may utilize heat or mechanical force. Since each blister cavity **305** is formed adjacent to a film segment **315**, upon cavity formation the segment **315** is simultaneously deposited into the cavity **305**.

In another technique, a film **310** is placed over a blister cavity-free substrate material. A machine forms blister cavities **305** in the substrate material while also displacing a film

20 segment **315** from the film **310** into each blister cavity **305**. In one embodiment, the blister cavities **305** are formed by drawing the substrate material **300** into an orifice, as discussed above. At approximately the same time, film segments **315** are displaced from the film **310** by impinging a punch **330** against the film **310** on a side opposite the substrate material **300**. The shape of the punch may be chosen to create a desired film segment size. The punch **330**

25 may have a surface that impinges upon the film **310** that is flat or curved. The punch contact surface may also have the shape of an annular ring or frame of any desired shape or size. The punch **330** preferably has edges that are sharp enough to cut the film **310**. The punch **330** forms film segments **315** that are deposited into the blister cavities **305**. The punch **330** is subsequently withdrawn.

30 In a third technique, a substrate material **300** with preformed blister cavities **305** is provided. The blister cavities **305** may be formed by any technique known in the art

including the particular technique described above. A film 310 with the therapeutic composition is positioned over the substrate material 300 on a side of the substrate material 300 in which the blister cavities 305 protrude away from the film 310, as depicted in Fig. 3a. A machine impinges the film 310 with a punch 330 on a side opposite the substrate material 300 in positions over the blister cavities 305. The punch contact creates a film segment 315 which is separated from the film 310 and deposited into the blister cavity 305.

Subsequent to the depositing of film segments into the blister cavities, a sealing material is used to contain the film segments within the cavities. The sealing material 320 may be any material that may be attached to the substrate material 300. In a particular embodiment, the sealing material 320 is heat sealable to the substrate material 300. One example of a sealing material 320 is lacquered aluminum foil. Other properties of the sealing material 320 that may be desirable include transparency and tear resistance.

The sealing material 320 is placed over openings of the blisters 305 that contain the film segments 315. Portions of the sealing material 320 are in contact with the substrate material 300. In a particular configuration, the sealing material 320 contacts the portions of the substrate 300 that do not constitute a blister cavity 305. Locations of contact between the sealing material 320 and substrate material 300 may be heat sealed, thus containing the film segments 315 within the blister cavities 305. The heat sealing may take place around each blister cavity to ensure isolation of each film segment. The corners of the substrate or sealing material may not be heat sealed to allow easier separation of the layers when access to the film segments is desired by a consumer.

The method may be practiced in a continuous process that forms a continuous substrate with blister cavities 305, film segments 315, and sealing material 320. A plurality of blister cavities 305 and/or film segments 315 may be formed in a batch process that is carried out successively. The continuous method would include the step of cutting the substrate 300 to provide discrete sets of the film segments 315.

In an alternative to this blister packaging method, the film segments are preformed and deposited into preformed blister cavities in a substrate material. In this embodiment, the method and device are not necessarily limited to the packaging of film segments but may include packaging of therapeutic compositions in other forms including patches, tablets, and pills.

The aforementioned embodiments are intended to be merely exemplary; numerous variations and modifications will be apparent to those skilled in the art. All such variations and modifications are intended to be within the scope of the present invention.

01581/00135 245114.1

Attorney Docket: 1581/135

Methods and Devices for Holding a Therapeutic Composition**Abstract**

Methods and devices for holding a therapeutic composition are described. A first
5 embodiment involves a support substrate that supports a discrete array of film segments
having the therapeutic composition, the film segments being attached to the support substrate
by a pattern of adhesive. A second embodiment involves a support substrate that supports a
discrete array of film segments having the therapeutic composition without the use of an
adhesive; the embodiment includes the use of a sealing material that is heat sealed to the
10 support substrate to contain the film segments. A third embodiment involves a substrate
holding the film segments in blisters; a sealing material is attached to the substrate to contain
the segments in the blisters.




FIGURE 1a




FIGURE 1b




FIGURE 2a




FIGURE 2b




FIGURE 2c

